Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946636 | 1.00 | MAPT (0.49) | MAPTKDM4EGAAKMT2AMEN1 | |
| SCHEMBL7068432 | 1.00 | MAPT (0.49) | MAPTKDM4EGAAKMT2AMEN1 | |
| SCHEMBL6954285 | 0.88 | ALDH1A1 (0.50) | MAPTALDH1A1SMN1; SMN2LIPEPOLB | |
| SCHEMBL7067800 | 0.88 | ALDH1A1 (0.50) | MAPTALDH1A1SMN1; SMN2LIPEPOLB | |
| SCHEMBL6954284 | 0.88 | ALDH1A1 (0.50) | MAPTALDH1A1SMN1; SMN2LIPEPOLB | |
| SCHEMBL6956004 | 0.87 | GAA (0.44) | GAAKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7069426 | 0.87 | GAA (0.44) | GAAKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6956005 | 0.87 | GAA (0.44) | GAAKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7065490 | 0.83 | DPP4 (0.44) | POLB | |
| SCHEMBL7065488 | 0.83 | DPP4 (0.44) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | THOMPSON LORIN A (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
| EP-1268454-A1 | SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074796-A1 | SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | MAPT 28/4885KDM4E 3430/4885GAA 156/4885 |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | MAPT 28/4885KDM4E 3430/4885GAA 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.